<DOC>
	<DOCNO>NCT02448810</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability BAX69 combination 5-fluorouracil ( 5-FU ) /leucovorin ( LV ) panitumumab determine recommend phase II dose ( RP2D ) combination ; compare efficacy BAX69 combination 5-FU/LV subject KRAS NRAS mutate tumor ( mt ) panitumumab , subject KRAS NRAS wild type tumor ( wt ) standard care ( SoC ) per investigator choice third fourth treatment line subject progressive measurable metastatic colorectal cancer ( mCRC ) .</brief_summary>
	<brief_title>Phase 2a Study BAX69 5-FU/Leucovorin Panitumumab Versus Standard Care Subjects With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Provision sign informed consent 2 . Male female subject 18 year age old time screen 3 . Subjects progress receive least 2 , 3 , prior SoC treatment line 4 . Anticipated life expectancy &gt; 3 month time screen 5 . Weight 40 kg 180 kg 6 . Histologically cytologically confirm diagnosis CRC 7 . Metastatic CRC amenable surgical resection 8 . Known KRAS NRAS mutation status ( unknown status either gene , archival tissue available , fresh tumor biopsy make ) 9 . At least 1 measurable lesion define RECIST v1.1 10 . ECOG PS 02 11 . Adequate hematological function , define : 1 . Platelet count ≥ 100,000/μL 2 . Prothrombin time activate partial thromboplastin time ( aPTT ) &lt; 1.5 time upper limit normal ( ULN ) 3 . Absolute neutrophil count ( ANC ) ≥ 1,000/μL 4 . Hemoglobin ≥ 9 g/dL , without need transfusion 2 week prior screen 12 . Adequate renal function , define serum creatinine ≤ 2.0 time ULN creatinine clearance &gt; 50 mL/min 13 . Adequate liver function , define : 1 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN subject without liver metastasis , ≤ 5 time ULN presence liver metastases 2 . Bilirubin ≤ 2.0 time ULN , unless subject know Gilbert 's syndrome 14 . Adequate venous access 15 . For female subject childbearing potential , subject present negative serum pregnancy test screen agrees employ 2 form adequate birth control measure , include least 1 barrier method ( eg , diaphragm spermicidal jelly foam , [ male partner ] condom ) throughout course study least 90 day last administration BAX69 . Other acceptable contraceptive measure include birth control pills/patches intrauterine device 16 . For male subject , subject must agree use adequate contraceptive measure include least 1 barrier method ( eg , condom spermicidal jelly foam [ female partner ] diaphragm spermicidal jelly foam , birth control pills/patches , intrauterine device ) abstain sperm donation throughout course study least 90 day last administration BAX69 17 . Subject willing able comply requirement protocol . 1 . Known central nervous system metastases 2 . Prior malignancy ( ) within past 3 year , exception curatively treat basal squamous cell carcinoma skin , locally advanced prostate cancer , ductal carcinoma situ breast , situ cervical carcinoma superficial bladder cancer 3 . Prior treatment panitumumab subject KRAS NRAS wt tumor 4 . Residual AE previous treatment &gt; Grade 1 5 . Prior intolerance fluoropyrimidine subject KRAS NRAS mut tumor 6 . Myocardial infarction within 6 month prior C1D1 , and/or prior diagnosis congestive heart failure ( New York Heart Association Class III IV ) , unstable angina , unstable cardiac arrhythmia require medication ; and/or subject risk polymorphic ventricular tachycardia ( eg , hypokalemia , family history long QT syndrome ) 7 . Uncontrolled hypertension define systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg confirm upon repeat measure 8 . LVEF &lt; 40 % determine echocardiogram perform screen within 90 day prior C1D1 9 . QT/QTc interval &gt; 450 msec , determine screen ECG perform earlier 1 week C1D1 10 . Prior antitumor therapy ( chemotherapy , radiotherapy , antibody therapy , molecular target therapy , retinoid therapy hormonal therapy ) within 4 week prior C1D1 . 11 . Major surgery within 4 week prior C1D1 12 . Active joint inflammation history inflammatory arthritis immune disorder involve joint 13 . Active infection involve IV antibiotic within 2 week prior C1D1 14 . Known history , active hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) active tuberculosis 15 . Known history human immunodeficiency virus ( HIV ) type 1/2 immunodeficiency disease 16 . Subject receive live vaccine within 4 week prior C1D1 17 . Known hypersensitivity component recombinant protein production CHO cell 18 . Exposure investigational product investigational device another clinical study within 4 week prior C1D1 , schedule participate another clinical study involve investigational product device course study 19 . Subject nursing intend begin nurse course study 20 . Any disorder disease , clinically significant abnormality laboratory clinical test ( ) ( eg , blood test , ECG ) , medical judgment investigator may impede subject 's participation study , pose increase risk subject , and/or confound result study 21 . Subject family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>